TRCT
COGT icon

Tower Research Capital (TRC)’s Cogent Biosciences COGT Stock Holding History

Tower Research Capital (TRC)’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$388K Sell
10,035
-9,362
-48% -$328K 0.01% 1204
2026
Q1 		$747K Buy
19,397
+11,834
+156% +$437K 0.02% 672
2025
Q4 		$269K Buy
7,563
+182
+2% +$5.12K 0.01% 1224
2025
Q3 		$106K Sell
7,381
-10,424
-59% -$123K ﹤0.01% 1941
2025
Q2 		$128K Buy
17,805
+12,613
+243% +$69.9K ﹤0.01% 2175
2025
Q1 		$31.1K Sell
5,192
-6,975
-57% -$54.7K ﹤0.01% 2578
2024
Q4 		$94.9K Buy
12,167
+11,562
+1,911% +$115K ﹤0.01% 2170
2024
Q3 		$6.53K Sell
605
-21,759
-97% -$212K ﹤0.01% 4136
2024
Q2 		$189K Buy
22,364
+19,720
+746% +$150K ﹤0.01% 2119
2024
Q1 		$17.8K Sell
2,644
-37,212
-93% -$230K ﹤0.01% 3099
2023
Q4 		$234K Buy
39,856
+36,939
+1,266% +$283K ﹤0.01% 1966
2023
Q3 		$28.4K Buy
2,917
+979
+51% +$11.6K ﹤0.01% 3063
2023
Q2 		$22.9K Sell
1,938
-1,092
-36% -$12.5K ﹤0.01% 3263
2023
Q1 		$33K Sell
3,030
-88
-3% -$1.13K ﹤0.01% 2887
2022
Q4 		$36K Sell
3,118
-231
-7% -$2.86K ﹤0.01% 2580
2022
Q3 		$50K Buy
3,349
+323
+11% +$4.43K ﹤0.01% 3150
2022
Q2 		$27K Buy
3,026
+603
+25% +$4.12K ﹤0.01% 3468
2022
Q1 		$18K Buy
2,423
+981
+68% +$6.83K ﹤0.01% 3617
2021
Q4 		$13K Sell
1,442
-1,377
-49% -$12K ﹤0.01% 4157
2021
Q3 		$24K Sell
2,819
-5,345
-65% -$41K ﹤0.01% 3553
2021
Q2 		$66K Buy
+8,164
New +$69K ﹤0.01% 2781
2020
Q4 		– Sell
-2,267
Closed -$21K – 5151
2020
Q3 		$21K Sell
2,267
-1,830
-45% -$19.1K ﹤0.01% 3846
2020
Q2 		$8K Buy
+4,097
New +$7.6K ﹤0.01% 4095
2019
Q4 		– Sell
-5,401
Closed -$31K – 3645
2019
Q3 		$31K Buy
+5,401
New +$43.9K ﹤0.01% 2163
2019
Q2 		– Sell
-972
Closed -$17K – 3754
2019
Q1 		$17K Sell
972
-61
-6% -$1.04K ﹤0.01% 2355
2018
Q4 		$18K Buy
1,033
+922
+831% +$27.3K ﹤0.01% 2011
2018
Q3 		$5K Buy
111
+40
+56% +$2.25K ﹤0.01% 3104
2018
Q2 		$4K Buy
+71
New +$3.41K ﹤0.01% 3116

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Tower Research Capital (TRC)'s COGT Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Cogent Biosciences (COGT) stake by 48% in Q2 2026, selling an estimated $328K and leaving 10,035 shares worth $388K. The position accounts for 0.01% of the portfolio, ranked #1204.

Tower Research Capital (TRC) first reported a position in COGT in Q2 2018 and has held it in 28 quarters since. The position peaked at $747K in Q1 2026. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Tower Research Capital (TRC) held 10,035 shares of Cogent Biosciences worth $388K as of Q2 2026.
  • Tower Research Capital (TRC) sold 9,362 Cogent Biosciences shares in Q2 2026, an estimated $328K.
  • Cogent Biosciences made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1204 holding.
  • Tower Research Capital (TRC) first reported a position in Cogent Biosciences in Q2 2018 and has held it in 28 quarters since.
  • Tower Research Capital (TRC)'s Cogent Biosciences position peaked at $747K in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.